In this current study, we applied a preclinical MB49 syngeneic mouse model and found that BC-derived EVs are immunoactive and can prevent autologous tumor growth through a mechanism primarily mediated by CD8+ T lymphocytes. The gene discussed is CD8A; the disease is breast cancer.